Drug maker Krka posted sales of EUR 857.4 million in the first half of the year, an increase of 6% on the year before and a new six-month record, according to preliminary estimates.
Net profit was up by a third to EUR 236.2 million as operating profit (EBIT) fell nearly as much to EUR 139.2 million due to an increase in the inventories of raw materials, materials, bulk products, and products required for long-term uninterrupted supply of Krka’s pharmaceuticals in the Russian market. Krka shareholders today endorsed the management’s proposal to pay out a dividend of EUR 5.63 gross per share, up 12.6% from last year. The shareholders will thus get a total of EUR 175 million.
By: P.T., STA
